Key Documents

View All Documentation

1347700

USP

Irbesartan

Name: Irbesartan
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-Butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₅H₂₈N₆O

CAS Number:

138402-11-6

Molecular Weight:

428.53

NACRES:

NA.24

PubChem Substance ID:

329750189

UNSPSC Code:

41116107

MDL number:

MFCD00864464

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

grade

pharmaceutical primary standard

API family

irbesartan

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5nnn[nH]5

InChI

1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

InChI key

YOSHYTLCDANDAN-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

Application

Irbesartan USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Irbesartan Tablets
Irbesartan and Hydrochlorothiazide Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.

J C Gillis et al.

Drugs, 54(6), 885-902 (1998-01-09)

Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII. In patients with mild to moderate hypertension, once daily administration

Irbesartan and hydrochlorothiazide association in the treatment of hypertension.

Giuseppe Derosa et al.

Current vascular pharmacology, 7(2), 120-136 (2009-04-10)

Blood pressure (BP) is one of the most important and common vascular risk factors but it is often poorly controlled. Inhibition of the renin-angiotensin-aldosterone system (RAAS) provides beneficial effects in hypertensives. The association of low-dosed diuretics in combination with RAAS

Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.

Peter Bramlage et al.

Expert opinion on pharmacotherapy, 11(4), 521-535 (2009-12-25)

Guidelines recommend five antihypertensive drug classes, but which particular drug to choose is up to the treating physician. We aimed at an in-depth comparison of two frequently used angiotensin receptor blockers to provide evidence for this decision. Pharmacology of irbesartan

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

A J Palmer et al.

International journal of clinical practice, 61(10), 1626-1633 (2007-09-20)

The objective of the study was to determine the impact of irbesartan treatment on life expectancy (LE), costs and progression to end-stage renal disease (ESRD) in hypertensive type 2 diabetes patients. A peer-reviewed and published Markov model was used to

Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.

Andrea Hartner et al.

Biochimica et biophysica acta, 1842(4), 558-565 (2014-01-15)

Diabetes can disrupt endoplasmic reticulum (ER) homeostasis which leads to ER stress. ER stress-induced renal apoptosis seems to be involved in the development of diabetic nephropathy. The present study was designed to investigate the contribution of reduced ER stress to

View All Related Papers

Global Trade Item Number

SKU	GTIN
1347700-200MG	04061838730244

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service